| Company Name: |
Alfa Chemistry |
| Tel: |
1-516-6625404 |
| Email: |
support@alfa-chemistry.com |
|
| | N-[12-[(7-Nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sphinganine Basic information |
| Product Name: | N-[12-[(7-Nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sphinganine | | Synonyms: | NBD-C12-SAFINGOL;N-ACYL-SPHINGANINE (C12 NBD);N-(NBD-AMINOLAUROYL)SAFINGOL;N-(NBD-AMINOLAUROYL)SPHINGANINE;N-[12-[(7-NITRO-2-1,3-BENZOXADIAZOL-4-YL)AMINO]DODECANOYL]-L-THREO-SPHINGANINE;N-[6-[(7-NITRO-2-1,3-BENZOXADIAZOL-4-YL)AMINO]DODECANOYL]-L-THREO-SPHINGANINE;C12 NBD dihydro Ceramide (d18:0/12:0);N-[12-[(7-NITRO-2-1,3-BENZOXADIAZOL-4-YL)AMINO]DODECANOYL]-SPHINGANINE;C12-NBD SPHINGANINE | | CAS: | 474943-05-0 | | MF: | C36H63N5O6 | | MW: | 661.92 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![N-[12-[(7-Nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sphinganine Structure](StructureFile/ChemBookStructure5/GIF/CB8179463.gif) |
| | N-[12-[(7-Nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sphinganine Chemical Properties |
| density | 1.095±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMF: 30 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml | | form | A solid | | pka | 14.30±0.20(Predicted) | | Appearance | Solid Powder |
| Hazard Codes | Xn | | Risk Statements | 22-38-40-48/20/22 | | Safety Statements | 36/37 | | RIDADR | UN 1888 6.1/PG 3 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | N-[12-[(7-Nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sphinganine Usage And Synthesis |
| Description | N-(NBD-Aminolauroyl)safingol is a fluorescent group C12 NBD-tagged probe for labeling membranous fatty acid phospholipids. | | Uses | C-12 NBD-dihydro-Ceramide is a fluorescent ceramidase substrate. C-12 NBD-dihydro-Ceramide compound is a fluorescent ceramide analog which contains a saturated bond in the C4-C5 position of the sphingosine backbone. It can be used for the measurement of alkaline and neutral ceramidase activity from a variety of sources. C-12 NBD-dihydro-ceramide may exhibit reduced activity in ceramidase assays compared to C-12 NBD ceramide. This is based on the observation that saturation of the C4-C5 sphingosine bond in C16-ceramide results in approximately a 10-fold reduction in efficiency as a substrate for rat brain ceramidase compared to the unsaturated substrate. Yet, experimental characterization of C-12 NBD-dihydro-ceramide as a ceramidase substrate needs to be performed. |
| | N-[12-[(7-Nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sphinganine Preparation Products And Raw materials |
|